As expected, emaciation and weight loss were less severe with PJ34 than with saline injection (P < 0.01; Fig. 3C, 3D), and the median survival of AML mice treated with PARP-1 inhibitor PJ34 was prolonged as compared to control mice (37.5 vs. 23.5 days, P < 0.01; Fig. 3E). This evidence concerns the gene PARP1 and acute myeloid leukemia.